Drugs / Targeted CEA CAR-T
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06992583 | May 2025 → Feb 2028 expected | lung cancer | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06945523 | Apr 2025 → Dec 2027 expected | lung cancer | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06903117 | Mar 2025 → Dec 2027 expected | lung carcinoma | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06768151 | Dec 2024 → Dec 2026 expected | lung cancer | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Targeted CEA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06992583 ↗ |
| Action | Deplete | “CAR-T cell preparations had a certain killing effect on CEA positive tumor cells” NCT06768151 ↗ |
| Modality | Cell therapy | “CAR-T cell preparations” NCT06768151 ↗ |
| Route | Intravenous | “intravenous CEA CAR-T therapy” NCT06768151 ↗ |